🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Takeda Development Center Americas clinical trials

Source: the EU Clinical Trials Information System (CTIS) — current trials in our EU (CTIS) register with Takeda Development Center Americas as lead sponsor. Synced 26 Sep 2026
4Current trials
0Recruiting now
1Drug in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Takeda Development Center Americas is the lead sponsor of 4 current clinical trials in our EU (CTIS) register. The drugs named most often in its trials are Zasocitinib.

Company profile on this site (news, sites, medicines, approvals): Takeda Ireland (IE) →
01

Takeda Development Center Americas in the EU trials register (CTIS)

4 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Takeda Development Center Americas as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke
2025-522734-31-00 · Nervous System Diseases
Phase 2 Authorised Greece, Belgium, France + 1 more
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
2025-522587-33-00 · CTIS ↗ · Nervous System Diseases
Phase 2 Authorised Spain, Italy, France
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
2025-522586-30-00 · CTIS ↗ · Musculoskeletal Diseases
Phase 3 Ongoing Germany, Belgium, Spain + 10 more
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
2025-522831-33-00 · CTIS ↗ · Skin and Connective Tissue Diseases
Phase 2 Authorised France, Poland, Netherlands + 1 more
02

Drugs in Takeda Development Center Americas trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

By trial register

RegisterTrialsRecruiting
EU register (CTIS)4—

A trial with sites in more than one country appears in each of those registers.

04

Questions about Takeda Development Center Americas trials

How many clinical trials does Takeda Development Center Americas sponsor?

Takeda Development Center Americas is the lead sponsor of 4 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Which drugs is Takeda Development Center Americas testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Zasocitinib (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.